Bratisl Lek Listy published in 2010 a number of remarkable papers related to malignancy but, for a good reason, nothing on the vitamin B 17 (1, 2) . Various other Slovak and foreign periodicals advertised recommendations for a product derived from almonds designed "vitamin B 17". Sequential designation "17" is as problematic as the claim for this compound to be biologically effective, allegedly for various types of cancer.
Mass produced advertisements under the attractive title WORLD WITH-OUT CANCER (Griffi n) have promoted the misleading idea of cancer being a variant of defi ciency -like scurvy or pellagra -aggravated by the lack of an "essential" food compound , vitamin B17 -also called laetrile. Carried to extreme, such "hypothesis" would mean that most global mortality of cancer is from defi ciency of vitamin B17, i.e. an inadequate regular consumption of almonds. Consequently, despite serious criticism in science circles, laetrile has been widely used among cancer patients (e.g. by many US citizens in Mexico) in the hope that it might stop or slow the process of malignant disease.
This compound is one of cyanogenic glucosides. Its history is long. It was isolated from bitter almonds in 1830. In 1949, the amygdalin extract was granted an US patent. The cyanide in amygdalin was supposed to kill cancer cells. Scientifi c criticism mounted and in 1953 California condemned its use and laetrile was declared illegal.
Given the lack of its biological effectiveness, laetrile has not been approved by the U.S. Food and Drug Administration. The U.S. National Institutes of Health evaluated the evidence separately and concluded that clinical trials of amgydalin showed little or no effect against cancer. In 1982, a trial of 178 patients found that the tumor size had increased in all patients and the authors reported that the hazards of amygdalin therapy were evidenced in several patients by symptoms of cyanide toxicity or by blood cyanide levels approaching the lethal range (3). The authors concluded "Patients exposed to this agent should be instructed about the danger of cyanide poisoning, and their blood cyanide levels should be carefully monitored. Amygdalin (laetrile) is a toxic drug that is not effective as a cancer treatment".
Numerous reports in the past denied the effectiveness of laetrile and warned about the risk of its use. Figure 1 indicates that the molecular structure of laetrile resembles amygdaline. It includes cyanide (CN in the circle on Fig.1 ) which is metabolized in the organism as a highly toxic compound. As long ago as in 1977, there was a report of a tragic outcome in an 11 months old baby who incidentally swallowed fi ve tablets (2.5 g) of laetrile. Subsequently the child developed a cyanide coma and died in three days. Tragic consequences of laetrile overdose are numerous (4-6).
The claim that laetrile has benefi cial effects for cancer has not been supported by sound clinical data (7-9). Laetrile neither caused shrinkage of tumours, nor alleviated cancer symptoms. Laetrile has caused serious, life-threatening toxicity. In light of the lack of effi cacy of laetrile and its demonstrated ability to cause harm, laetrile should not be used to treat cancer. According to Greenberg (9), the writings of laetrile proponents are fi lled with erroneous and absurd statements. The propaganda for the doctrine of "freedom of choice in cancer treatment" deludes many individuals with treatable cancer and they may reject proven methods of treatment".
The label "unproven" is inappropriately defensive for laetrile therapy; it is time to vehemently assert that laetrile cancer therapy has been "disproven." (9, 10). On the basis of an extensive data search we propose that this "wondrous vitamin B 17" is banned by regulatory authorities in the Slovak Republic.
